carfilzomib and delanzomib share 6 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.429 means 43% of the combined target set is bound by both compounds. The IDF-weighted score of 0.446 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do carfilzomib and delanzomib have in common?
carfilzomib and delanzomib share 6 molecular targets with a Jaccard similarity of 43%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can carfilzomib and delanzomib be combined?
carfilzomib and delanzomib share 6 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: carfilzomib or delanzomib?
In the BiohacksAI corpus: carfilzomib has 0 PubMed-indexed studies, delanzomib has 0 studies.